Lung Cancer最新文献

{"title":"Asbestos-Related lung Cancer: An underappreciated oncological issue","authors":"Nico van Zandwijk ,&nbsp;Arthur L. Frank ,&nbsp;Glen Reid ,&nbsp;Oluf Dimitri Røe ,&nbsp;Christopher I. Amos","doi":"10.1016/j.lungcan.2024.107861","DOIUrl":"https://doi.org/10.1016/j.lungcan.2024.107861","url":null,"abstract":"<div><p>Asbestos, a group of class I (WHO) carcinogenic fibers, is the main cause of mesothelioma. Asbestos inhalation also increases the risk to develop other solid tumours with lung cancer as the most prominent example <span>[91]</span>. The incidence of asbestos-related lung cancer (ARLC) is estimated to be to six times larger than the mesothelioma incidence thereby becoming an important health issue <span>[86]</span>. Although the pivotal role of asbestos in inducing lung cancer is well established, the precise causal relationships between exposures to asbestos, tobacco smoke, radon and ‘particulate’ (PM2.5) air pollution remain obscure and new knowledge is needed to establish appropriate preventive measures and to tailor existing screening practices<span>[22]</span>, <span>[61]</span>, <span>[65]</span>. We hypothesize that a part of the increasing numbers of lung cancer diagnoses in never-smokers can be explained by (historic and current) exposures to asbestos as well as combinations of different forms of air pollution (PM2.5, asbestos and silica).</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107861"},"PeriodicalIF":4.5,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169500224003957/pdfft?md5=082a9bfe44f84f001f9371ff106da216&pid=1-s2.0-S0169500224003957-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141607228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study","authors":"Elvire Pons-Tostivint ,&nbsp;Remy Ezzedine ,&nbsp;Thomas Goronflot ,&nbsp;Perrine Crequit ,&nbsp;Thierry Chatellier ,&nbsp;Judith Raimbourg ,&nbsp;Jaafar Bennouna ,&nbsp;Etienne Giroux Leprieur ,&nbsp;Marie Porte","doi":"10.1016/j.lungcan.2024.107887","DOIUrl":"https://doi.org/10.1016/j.lungcan.2024.107887","url":null,"abstract":"<div><h3>Introduction</h3><p>Chemotherapy combined with immunotherapy (CT-IO) is the standard treatment for patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). This study evaluates the effectiveness of second-line (2L) following CT-IO.</p></div><div><h3>Patients and Methods</h3><p>All patients from 10 centers who received a 2L after a first-line CT-IO were included. They were divided into 3 groups: platinum-based, lurbinectedin or others (topotecan, CAV, taxanes). We assessed overall survival (OS) and 2L progression-free survival (2L-PFS) according to treatment and platinum free-interval (PFI) <span><math><mo>&lt;</mo></math></span> or <span><math><mo>≥</mo></math></span> 90 days.</p></div><div><h3>Results</h3><p>Among 82 patients included, median age was 67.0 years, 29.3 % had a Performans Status ≥ 2, 36.6 % had brain progression, 69.5 % were considered “platine-sensitive” and 30.5 % “platine-resistant” (PFI ≥ or <span><math><mo>&lt;</mo></math></span> 90 days, respectively). As 2L, 37/82 patients (45.1 %) received platinum-doublet, 21/82 (25.6 %) lurbinectedin and 24/82 (29.3 %) others. Patients with a PFI ≥ 90 days received mainly platinum-based rechallenge (34/57, 59.6 %). With a median follow-up of 18.5 months, the median OS was 5.0 months (95 %CI, 1.5–7.9) / 6.8 months (95 %CI, 5.5–8.7) for platinum-resistant / sensitive, respectively (log rank p = 0.017). The median 2L-PFS was 1.9 months (95 %CI, 1.2–4.7) / 3.9 months (95 %CI, 2.9–6.0) for platinum-resistant / sensitive, respectively. Median OS was 8.1 (95 %CI, 6.3–12.9) / 4.9 (95 %CI, 3.7–6.8) / 5.1 months (95 %CI, 2.5–7.8) with platinum rechallenge / lurbinectedin / others, respectively (p = 0.017). Median 2L-PFS was 4.6 (95 %CI, 3.9–7.2) / 2.7 (95 %CI, 1.6–3.9) / 2.2 months (95 %CI, 1.5–4.1) with platinum rechallenge / lurbinectedin / others, respectively (p = 0.025).</p></div><div><h3>Discussion</h3><p>Platinum-based rechallenge after a first-line CT-IO showed promising results despite particularly unfavorable characteristics within our real-word population. Lurbinectedin when used after IO demonstrated as low efficacy as other platinum-free regimens.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107887"},"PeriodicalIF":4.5,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer","authors":"Motohiro Izumi,&nbsp;Daniel B. Costa,&nbsp;Susumu S. Kobayashi","doi":"10.1016/j.lungcan.2024.107885","DOIUrl":"10.1016/j.lungcan.2024.107885","url":null,"abstract":"<div><p>The advent of targeted therapies revolutionized treatments of advanced oncogene-driven non-small cell lung cancer (NSCLC). Nonetheless, despite initial dramatic responses, development of drug resistance is inevitable. Although mechanisms underlying acquired resistance, such as on-target mutations, bypass pathways, or lineage transformation, have been described, overcoming drug resistance remains challenging. Recent evidence suggests that drug-tolerant persister (DTP) cells, which are tumor cells tolerant to initial drug exposure, give rise to cells that acquire drug resistance. Thus, the possibility of eradicating cancer by targeting DTP cells is under investigation, and various strategies are proposed. Here, we review overall features of DTP cells, current efforts to define DTP markers, and potential therapeutic strategies to target and eradicate DTP cells in oncogene-driven NSCLC. We also discuss future challenges in the field.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107885"},"PeriodicalIF":4.5,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis","authors":"Rongzhen Li ,&nbsp;Yan Xu ,&nbsp;Jing Zhao ,&nbsp;Li Zhang ,&nbsp;Wei Zhong ,&nbsp;Xiaoxing Gao ,&nbsp;Xiaoyan Liu ,&nbsp;Minjiang Chen ,&nbsp;Mengzhao Wang","doi":"10.1016/j.lungcan.2024.107884","DOIUrl":"https://doi.org/10.1016/j.lungcan.2024.107884","url":null,"abstract":"<div><h3>Background</h3><p>Neoadjuvant chemoimmunotherapy followed by surgery is recommended for resectable non-small-cell lung cancer (NSCLC). However, a considerable proportion of patients do not undergo surgery and opt for alternative treatments such as radiotherapy. The efficacy of radiotherapy in this context remains unclear.</p></div><div><h3>Methods</h3><p>This retrospective study analyzed data from patients with stage III NSCLC who received neoadjuvant chemoimmunotherapy followed by either surgery or radiotherapy. Propensity score matching (PSM) was used to balance the heterogeneity between the groups. Efficacy outcomes, safety profiles, and disease recurrence patterns were assessed.</p></div><div><h3>Results</h3><p>In total, 175 patients were included; 50 underwent radiotherapy, and 125 underwent surgery. Prior to matching, radiotherapy was inferior to surgery in terms of progression-free survival (PFS; Hazard ratio [HR], 2.23; <em>P</em> = 0.008). Following a 1:1 PSM adjustment, each group consisted of 40 patients. The median PFS was 30.8 months in the radiotherapy group and not reached in the surgery group (HR, 1.46; <em>P</em> = 0.390). The 12- and 24-month PFS rates were 90.4 % and 69.0 % for the radiotherapy group compared to 94.1 % and 73.9 % for the surgery group, respectively. Subgroup analyses after PSM showed that patients with stage IIIA disease tend to benefit more from surgery than those with stage IIIB disease (HR, 3.00; <em>P</em> = 0.074). Grade 3–4 treatment-related adverse events (TRAEs) occurred in 62.5 % of patients in the radiotherapy group and 55.0 % in the surgery group, with no grade 5 TRAEs reported. The incidence of grade 3–4 treatment-related pneumonitis or pneumonia was 7.5 % and 2.5 % in the radiotherapy and surgery groups, respectively.</p></div><div><h3>Conclusion</h3><p>Radiotherapy may be a viable alternative to surgery in patients with resectable NSCLC who do not undergo surgical resection after initial neoadjuvant chemoimmunotherapy, offering comparable efficacy and a manageable safety profile. Larger prospective studies are needed to validate these findings and optimize the treatment strategies for this patient population.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107884"},"PeriodicalIF":4.5,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169500224004185/pdfft?md5=9a915acf81917d1f44f7bb00f097bec7&pid=1-s2.0-S0169500224004185-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)","authors":"Yu Jung Kim ,&nbsp;Soyeon Kim ,&nbsp;Tae Min Kim ,&nbsp;Koung Jin Suh ,&nbsp;Miso Kim ,&nbsp;Se Hyun Kim ,&nbsp;Bhumsuk Keam ,&nbsp;Dong-Wan Kim ,&nbsp;Jong Seok Lee ,&nbsp;Dae Seog Heo","doi":"10.1016/j.lungcan.2024.107870","DOIUrl":"10.1016/j.lungcan.2024.107870","url":null,"abstract":"<div><h3>Background</h3><p>Epidermal growth factor receptor (<em>EGFR)</em> exon 20 insertions account for up to 10% of all <em>EGFR</em> mutations. Clinical outcomes in patients receiving approved <em>EGFR</em> exon 20 insertion–specific inhibitors have been variable. Although osimertinib has demonstrated antitumor activity in clinical trials, its clinical efficacy and translational potential remain to be determined in non-small cell lung carcinoma (NSCLC) with <em>EGFR</em> exon 20 insertion.</p></div><div><h3>Methods</h3><p>In this multicenter phase II study, patients with advanced NSCLC harboring <em>EGFR</em> exon 20 insertions for whom the standard chemotherapy failed received 80 mg osimertinib once daily. The primary endpoint was the investigator-assessed objective response rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors version 1.1. The secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety profile.</p></div><div><h3>Results</h3><p>Among 15 patients enrolled at stage 1, the best response was most commonly disease stabilization (73.3 %), which did not meet the stage 1 threshold (objective response ≥ 2/15). As of data cutoff, two patients remained on the treatment. The median PFS and OS were 3.8 (95 % confidence interval [CI] = 1.7–5.5) months and 6.5 (95 % CI = 3.9–not reached) months, respectively. Adverse events (≥grade 3) were anemia, hypercalcemia, and pneumonia (13.3 % each), and asthenia, femur fracture, increased alkaline phosphate, hyperkalemia, bone pain, and azotemia (6.7 % each). Pre-existing <em>EGFR</em> C797S mutation detected in plasma limited the efficacy of osimertinib.</p></div><div><h3>Conclusion</h3><p>Osimertinib at 80 mg once daily had limited efficacy and mostly showed disease stabilization with an acceptable safety profile in advanced NSCLC harboring <em>EGFR</em> exon 20 insertions.</p><p><span><strong>ClinicalTrials.gov</strong></span><svg><path></path></svg> <strong>Identifier:</strong> NCT03414814.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107870"},"PeriodicalIF":4.5,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative oncology for patients with lung cancer: A prospective pragmatic controlled trial","authors":"Eran Ben-Arye ,&nbsp;Orit Gressel ,&nbsp;Shahar Lifshitz ,&nbsp;Nir Peled ,&nbsp;Shoshana Keren ,&nbsp;Noah Samuels","doi":"10.1016/j.lungcan.2024.107857","DOIUrl":"10.1016/j.lungcan.2024.107857","url":null,"abstract":"<div><h3>Introduction</h3><p>Complementary medicine and integrative oncology modalities (IOM) have been included in the clinical practice guidelines of the American College of Chest Physicians in the treatments of patients with lung cancer. The present study examined the impact of a patient-tailored IOM treatment program on quality of life (QoL)-related concerns among patients with non-small and small lung cancer undergoing active oncology treatment.</p></div><div><h3>Methods</h3><p>This controlled study was pragmatic and prospective assessing the adherence among patients referred by their oncology healthcare provider to an integrative physician consultation, followed by 6 weekly IOM treatments addressing QoL-related concerns. High adherence to integrative care (high-AIC, vs. low-AIC) was defined as attending ≥4 IOM sessions. Symptoms were assessed using the ESAS (Edmonton Symptom Assessment Scale), EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire), and MYCAW (Measure Yourself Concerns and Wellbeing) tools, at baseline and 6 weeks.</p></div><div><h3>Results</h3><p>Of 153 patients, 74 (48 %) were high-AIC, with baseline demographic, cancer-and QoL-related characteristics similar to those of low-AIC patients. At 6 weeks, high-AIC patients reported greater improvement on MYCAW well-being (p = 0.036), with within-group improvement observed for EORTC pain (p = 0.021) and emotional functioning (p = 0.041); and for ESAS depression (p = 0.005), with borderline significance for EORTC sleep (p = 0.06).</p></div><div><h3>Conclusion</h3><p>High adherence to a 6-week IOM program within supportive/palliative care for patients with lung cancer was found to alleviate pain and emotional concerns, improving overall QoL. Further research is needed to confirm the findings in real-life IOM practice for patients with lung cancer.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"193 ","pages":"Article 107857"},"PeriodicalIF":4.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]","authors":"Masayuki Takeda ,&nbsp;Mototsugu Shimokawa ,&nbsp;Atsushi Nakamura ,&nbsp;Kaname Nosaki ,&nbsp;Yasutaka Watanabe ,&nbsp;Terufumi Kato ,&nbsp;Daisuke Hayakawa ,&nbsp;Hiroshi Tanaka ,&nbsp;Toshiaki Takahashi ,&nbsp;Masahide Oki ,&nbsp;Motoko Tachihara ,&nbsp;Daichi Fujimoto ,&nbsp;Hidetoshi Hayashi ,&nbsp;Kakuhiro Yamaguchi ,&nbsp;Shoichiro Yamamoto ,&nbsp;Eiji Iwama ,&nbsp;Koichi Azuma ,&nbsp;Kazuo Hasegawa ,&nbsp;Nobuyuki Yamamoto ,&nbsp;Kazuhiko Nakagawa","doi":"10.1016/j.lungcan.2024.107852","DOIUrl":"10.1016/j.lungcan.2024.107852","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"193 ","pages":"Article 107852"},"PeriodicalIF":4.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169500224003866/pdfft?md5=c09258544ed0a314ddfbf02e05fc17c8&pid=1-s2.0-S0169500224003866-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report","authors":"Chinatsu Yoshizaki ,&nbsp;Yuki Yoshida ,&nbsp;Shiho Nohmi ,&nbsp;Yoshihiro Go ,&nbsp;Rui Kusakado ,&nbsp;Saori Kawamura ,&nbsp;Daisuke Inoue ,&nbsp;Nobuyuki Kabasawa ,&nbsp;Fumihiro Yamaguchi","doi":"10.1016/j.lungcan.2024.107869","DOIUrl":"https://doi.org/10.1016/j.lungcan.2024.107869","url":null,"abstract":"<div><p>Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107869"},"PeriodicalIF":4.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141540288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis","authors":"Jacob Aptekar ,&nbsp;Rahul Jain ,&nbsp;Beata Korytowsky ,&nbsp;Afrah Shafquat ,&nbsp;Jacob Hendershot ,&nbsp;Aniketh Talwai ,&nbsp;Yahav Itzkovich ,&nbsp;Sukhmani K. Padda","doi":"10.1016/j.lungcan.2024.107854","DOIUrl":"10.1016/j.lungcan.2024.107854","url":null,"abstract":"<div><h3>Objectives</h3><p>Limited data are available on central nervous system (CNS) efficacy with standard-of-care therapies for <em>KRAS-</em>mutated (<em>KRAS</em>mut) advanced non-small cell lung cancer (NSCLC). The objective of this study was to investigate the incidence and progression of brain metastases in <em>KRAS</em>mut advanced NSCLC treated with docetaxel using pooled data from historical clinical trials.</p></div><div><h3>Materials and Methods</h3><p>Data from phase 2/3 trials of docetaxel-containing regimens in advanced NSCLC were sourced from the Medidata platform. Analysis was restricted to stage IIIB-IV <em>KRAS</em>mut NSCLC with disease progression after ≥ 1 systemic anticancer therapy. Participants with asymptomatic, treated, and stable brain metastases were included. Endpoints included 12-month CNS disease control rate (CNS-DCR) and CNS progression per Response Evaluation Criteria in Solid Tumors; progression-free survival (PFS); and overall survival (OS). Data were pooled and analyses stratified by baseline brain metastases status.</p></div><div><h3>Results</h3><p>A total of 595 participants were included in the analysis (62 [10%] with baseline brain metastases and 533 [90 %] without). Among participants with brain metastases, 17 (27.4 %) had CNS progression during docetaxel treatment and 12-month CNS-DCR was 75.8 %; 45 (8.4 %) participants without baseline brain metastases developed brain metastases during treatment. In an analysis restricted to patients with metastatic disease, outcomes with and without baseline brain metastases included: median PFS, 3.3 and 4.9 months (p &lt; 0.005); 12-month PFS, 5 % and 16 %; median OS, 6.9 and 10.4 months (p &lt; 0.005); and 12-month OS, 20 % and 44 %, respectively.</p></div><div><h3>Conclusion</h3><p>These findings establish CNS progression rates with docetaxel in previously treated <em>KRAS</em>mut advanced NSCLC and facilitate interpretation of data from ongoing randomized clinical trials of novel KRAS-targeted therapeutic strategies vs. docetaxel.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"193 ","pages":"Article 107854"},"PeriodicalIF":4.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S016950022400388X/pdfft?md5=2621b4e0b9bc475a05829afcdbf6a7d3&pid=1-s2.0-S016950022400388X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141410025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial","authors":"Olivier Bylicki ,&nbsp;Florian Guisier ,&nbsp;Arnaud Scherpereel ,&nbsp;Catherine Daniel ,&nbsp;Aurélie Swalduz ,&nbsp;Emmanuel Grolleau ,&nbsp;Marie Bernardi ,&nbsp;Stephane Hominal ,&nbsp;Jean.Briac Prevost ,&nbsp;Guillaume Pamart ,&nbsp;Marie.Héléne Marques ,&nbsp;Nicolas Cloarec ,&nbsp;Simon Deshayes ,&nbsp;Judith Raimbourg ,&nbsp;Rémi Veillon ,&nbsp;Youssef Oulkhouir ,&nbsp;Clarisse Audigier Valette ,&nbsp;Fabien Subtil ,&nbsp;Christos Chouaïd ,&nbsp;Laurent Greillier","doi":"10.1016/j.lungcan.2024.107866","DOIUrl":"10.1016/j.lungcan.2024.107866","url":null,"abstract":"<div><h3>Background</h3><p>First-line standard-of-care for unresectable, pleural mesothelioma (PM) changed with the phase 3 CheckMate 743 study results, showing that nivolumab plus ipilimumab (Nivo + Ipi) significantly extended overall survival (OS) versus platinum + pemetrexed chemotherapy for PM (median OS 18.1 versus 14.1 months; hazard ratio: 0.74; <em>p</em> = 0.002). Efficacy and safety data in real-world (rw) settings are needed to confirm these results.</p></div><div><h3>Methods</h3><p>This French multicenter, retrospective cohort study was undertaken to assess the outcomes of treatment-naïve PM patients given Nivo + Ipi via an early-access program (EAP). The primary objective was investigator-assessed real world −progression-free survival (PFS). The secondary objectives were the combination’s −overall survival (OS) and safety.</p></div><div><h3>Results</h3><p>From 1 April 2021 to 15 Feb 2022, the analysis included 201 of the 305 EAP-enrolled patients treated in 63 centers (79.6 % men; median age: 75 years; 91.8 % Eastern Cooperative Oncology Group performance status (ECOG-PS) 0/1; 74.5 % epithelioid histology). With median (95 % CI) follow-up for all patients of 18.4 (17.7–19.2) months, −PFS and OS were 6.3 (5.3–7.5) and 18.9 (17.6–not reached (NR)) months, with 1-year OS at 66.4 % (60.1–73.3 %). Median OS and 1-year survival rates were 21.0 (18.7–NR) and 70.8 % (63.9 %-780.6 %), and 14.1 (10.9–21.0) months and 54.9 % (42.8 %–70.4 %) for epithelioid and non-epithelioid PM subgroups, respectively. PFS was equal between the two subgroups. Grade 3–4 adverse events occurred in 23.3 % of patients and three deaths were treatment-related.</p></div><div><h3>Conclusions</h3><p>For this unselected PM population, efficacy and safety outcomes compared favorably with CheckMate 743 trial results.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"194 ","pages":"Article 107866"},"PeriodicalIF":4.5,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0169500224004008/pdfft?md5=f5e526d17567761e429dcf6f0e020f85&pid=1-s2.0-S0169500224004008-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}